RAB6A and plasma cell myeloma: Since our study demonstrated that ZA treatment of human myeloma cells increases the abundance of the non-prenylated form of Rap1A and decreases the prenylated form of Rab6 [27], thus we treated 5TGM1 mouse myeloma cells with increased concentration of ZA as a positive control.